← Human Trials & Peer-Reviewed Studies

Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial.

Plain-language guide to PMID 38890228 (2024): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 148 men.

Key Facts

PMID
38890228
Journal
Journal of cachexia, sarcopenia and muscle
Year
2024
Study type
Randomized Controlled Trial
Authors
Midttun M et al. (13 authors)
DOI
10.1002/jcsm.13498

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The main outcome measure was the 30-s chair stand test, due to test performance correlating with the risk of serious fall injuries and lower extremity muscle strength.

Who Took Part

According to the abstract, 148 men were involved.

PubMed indexes the participants as older adults and people over 80, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Calcium, Dietary Proteins, Dietary Supplements, Exercise, Muscle Strength, Resistance Training and Testosterone.

Author keywords: elderly, falls, physical exercise and testosterone therapy.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 148 men.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Journal of cachexia, sarcopenia and muscle), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.